Insider trade

Artelo Biosciences (ARTL): Director received 292 units

Douglas Blayney, Director at Artelo Biosciences, reported a grant / award of 292 units.

292
Derivative units
Traded
Jan 30, 2026
Filed
Feb 2, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jan 14, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed, on December 31, 2025, Artelo Biosciences, Inc. (the “Company”) convened and then adjourned, without conducting any business, its 2025 annual meeting of stockholders (the “Annual Meeting”) due to insufficient votes to constitute a quorum.”
  2. Jan 30, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them

What came next

  1. Mar 5, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year (and 1 more item)
  2. Mar 12, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
  3. Mar 17, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  4. Mar 20, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
  5. Mar 27, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 2 more items)
  6. May 11, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  7. May 26, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Artelo Biosciences

OQRO holds no insider, Congress, fund or contract record for Artelo Biosciences dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARTL page.

How this filing works

Explore the data

Common questions

Which Artelo Biosciences (ARTL) insider traded, and how much?

Douglas Blayney, Director at Artelo Biosciences, reported a grant / award of 292 units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Jan 30, 2026. Filed: Feb 2, 2026. That is 3 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean ARTL stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data